Selection of blockbuster announcements

• $Alibaba Health Information Technology (00241.HK) $A net loss of 230 million yuan in the first half of the year

Alibaba Health Information Technology's revenue in the first half of the year was 9.36 billion yuan, up 31% from the same period last year; the net loss in the first half was 231.8 million yuan, compared with a profit of 283.4 million yuan in the same period last year; and the gross profit in the first half was 20%, compared with 26% in the same period last year.

• $Chinese Education Holdings (00839.HK) $Annual adjusted net profit increased by 57.1% to 1.55 billion yuan, with a final interest rate of HK20. 2 cents

Zhongjiao Holdings announced that for the year ended August 31, 2021, the company's revenue was 3.682 billion yuan, an increase of 37.5 percent over the same period last year. Its financial efficiency grew steadily, operating profit increased by 42.9 percent, and net profit increased by 107.2 percent. Adjusted net profit rose 57.1% year-on-year to 1.55 billion yuan, with a final dividend of HK20. 2 cents per common share.

• $XIAOMI Group-W (01810.HK) $A total of 59.7886 million award shares are awarded under the share incentive scheme

XIAOMI Group-W announced that the Board of Directors has awarded a total of 59788554 Award shares to 2024 selected participants under the share Award Scheme on 24 November 2021, of which 2023 selected participants are unrelated grantees and one selected participant is a connected grantee.

• $minimally invasive robot-B (02252.HK) $Mona Lisa prostate puncture robot clinical trial starts and completes the first operation

Minimally invasive Robotics announced that the company and Singapore Biobot Surgical Pte. Ltd. The Mona Lisa prostate puncture robot positioning system ("Mona Lisa") introduced by Shanghai Jiahang Robot Co., Ltd., a joint venture in China, has successfully held a clinical trial launching ceremony and completed the first operation in Gulou Hospital affiliated to the Medical College of Nanjing University ("Nanjing Gulou Hospital"). This is also the first clinical trial operation of prostate puncture biopsy assisted by robot in China.

• $Development Pharmaceutical Industry-B (09939.HK) $The key clinical trial of Fretaine in the treatment of androgenic alopecia has been approved by NMPA in China.

With the announcement of the pioneering pharmaceutical industry, the board of directors is pleased to announce that the key clinical trial (phase III clinical trial) for the treatment of androgenic alopecia ("AGA") with the approval of the State Drug Administration ("NMPA") of the State Drug Administration ("NMPA") has been approved by the board of directors. Freitain is the first topical androgen receptor (AR) antagonist in the world to enter the phase III clinical trial for AGA treatment.

Spin-off and listing

Xianeng Group (01730): it is proposed to spin off LHN Logistics and list independently on the Kelly board of the Singapore Stock Exchange.

Financial data

The adjusted net profit of Chinese Education Holdings (00839) increased by 57.1% to 1.55 billion yuan, with a final interest rate of HK20. 2 cents.

Alibaba Health Information Technology (00241) changed from profit to loss of 232 million yuan in the middle period, and the annual active consumers of online self-owned stores reached 90 million.

Huazhu Group Limited-S (01179) third quarter net loss narrowed to 137 million yuan

Oriental Watch Group (00398) medium-term net profit of HK $167 million increased by 186.79% compared with the same period last year.

South-South Resources (01229) medium-term net loss of HK $29.641 million increased by 40.21% compared with the same period last year.

The medium-term net profit of Zhenxiong Group (00057) rose 68% to HK5.2 cents of HK $123 million.

DYNAM JAPAN (06889): medium-term net profit 3.42 billion yen up 390% year-on-year

Kingsoft Industries (00040): medium-term continuing operating net profit of HK $55.5 million increased by 22.5%

Total expected medium-term income of Sizhou Group (00374) is about HK $2.354 billion.

Rich stone finance (02263) Yingxi: medium-term net profit increases by not less than 20%

Additional rights issue

Guangjun Group Holdings (08516) intends to merge shares with "10 in 1".

Investment and operation

Shanghai Fosun Pharmaceutical (02196) holding subsidiary plans to participate in private equity funds to invest in early innovative drug projects.

Shanghai Fosun Pharmaceutical (02196): Aohong Pharmaceutical Company voluntarily applied to withdraw the registration application of sodium cromoglycate granules.

Shanghai Fosun Pharmaceutical (02196) and his holding subsidiary plan to jointly invest with Ningbo Xingyao to set up an equity investment fund Dalian Rehabilitation

Hongguang Semiconductor (06908) invested $1.75 million in gallium nitride technology leader GaN Systems Inc.

Pioneering Pharmaceutical Industry-B (09939): the key clinical trial of Freitain in the treatment of androgenic alopecia has been approved by NMPA in China.

Minimally invasive robot-B (02252): Mona Lisa prostate puncture robot clinical trial starts and completes the first operation

Xianjian Technology (01302): Yuranos ™abdominal aorta covered stent system is registered and approved by the State Drug Administration of China.

Jinjiang Capital (02006) gains controlling shareholder premium of about 33.62% absorption merger resumes trading tomorrow

China Gas (00384) enters into a strategic cooperation framework agreement with Beijing Combustion Group

Fu Hong Hanlin (02696): HLX301 (Recombinant Human Anti-PD-L1 and Anti-TIGIT Bispecific Antibody injection) was approved to conduct clinical trials for locally advanced or metastatic solid tumors in Australia.

Jun Baiyan Group (08372) intends to subscribe for 0.95% of Techmetics shares and set up a joint venture

Rome Group (08072) has been granted the option to purchase shares in Alpha Excellent. It is proposed to change its name to "Rome (meta-universe)".

Ruifeng New Energy (00527): a total of 1.29 billion yuan has been collected for three phases.

Chuangsheng Group-B (06628): humanized anti-VEGFR-2 monoclonal antibody MSB0254 successfully completes phase Ib clinical trial

Tiantie Co., Ltd. (300587.SZ): sign a large order of 30.70898 million yuan damping pad

Haichang Ocean Park (02255) signs Fuzhou Gulou District Tourism Project Cooperation Framework Agreement

China Tongfu (01763): Qingdao Atomic Qualcomm Inc Medicine passes GMP Compliance Test

North-controlled urban resources (03718): won 35.85 million yuan market-oriented sanitation and cleaning project in Renhua, Shaoguan, Guangdong.

Repurchase cancellation

Ping An Insurance (02318): spent 22.5026 million yuan to buy back 455200 A shares on the 24th, for a total of 3.705 billion yuan

HSBC Holdings PLC (00005) spent 7.271 million pounds to buy back 1.653 million shares on November 23rd

Baifu Global (00327) spent HK $9.5157 million to buy back 1.466 million shares on November 24th

Liwen Paper (02314) spent HK $18.7627 million to buy back 3.461 million shares on November 24th

Net Dragon (00777) spent HK $3.454 million to buy back 200000 shares on November 24th

Lianyirong Technology-W (09959) spent HK $7.9886 million on November 24th to buy back 1.301 million shares

Equity incentive

XIAOMI Group-W (01810): a total of 59.7886 million award shares under the share incentive scheme